M
6.18
0.19 (3.17%)
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bearish |
| Biotechnology (Global) | Mixed | Bearish | |
| Stock | Mind Medicine (MindMed) Inc. | Bullish | Bullish |
Stockmoo Score
1.1
|
Mind Medicine Inc is a biopharmaceutical company. The company produces to treat brain health disorders. The company discovers, develops, and deploys psychedelic inspired medicines and therapies to address addiction and mental illness. The company is assembling a compelling drug development pipeline of treatments based on psychedelic substances. The firm is having an approach towards developing the next generation of psychedelic-inspired medicines and therapies. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Octagon Capital Advisors Lp | 30 Jun 2024 | 2,153,000 |
| Blackstone Inc. | 30 Jun 2024 | 1,898,325 |
| Ally Bridge Group (Ny) Llc | 30 Jun 2024 | 965,426 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 55.00 (HC Wainwright & Co., 789.97%) | Buy |
| Median | 45.50 (636.25%) | |
| Low | 36.00 (Roth MKM, 482.52%) | Buy |
| Average | 45.50 (636.25%) | |
| Total | 2 Buy | |
| Avg. Price @ Call | 7.37 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| HC Wainwright & Co. | 29 Aug 2024 | 55.00 (789.97%) | Buy | 6.01 |
| 31 Jul 2024 | 35.00 (466.34%) | Buy | 9.26 | |
| Roth MKM | 24 Jul 2024 | 36.00 (482.52%) | Buy | 8.72 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2024 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |